Within the category of AML-MRC, we found NPM1-A(+) in 36.4% of patients, similarly to Döhner et al., who found 5 patients with NPM1 mutations out of 13 (38.5%) with secondary AML following myelodysplastic syndrome [13]. The gene discussed is NPM1; the disease is myelodysplastic syndrome.